David B Agus

List of Publications by Year
in descending order

22 papers	715 citations	687363 13 h-index	677142 22 g-index
24 all docs	24 docs citations	24 times ranked	1401 citing authors

#	Article	IF	Citations
1	Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 61-68.	3.9	34
2	Cancer Moonshot 2.0. Lancet Oncology, The, 2021, 22, 164-165.	10.7	9
3	Paradoxical androgen receptor regulation by small molecule enantiomers. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	2
4	High-throughput microscopy reveals the impact of multifactorial environmental perturbations on colorectal cancer cell growth. GigaScience, 2021, 10, .	6.4	7
5	Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains. Nature Communications, 2020, 11, 5727.	12.8	126
6	Deep learned tissue â€œfingerprintsâ€•classify breast cancers by ER/PR/Her2 status from H&E images. Scientific Reports, 2020, 10, 7275.	3.3	60
7	Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA). BMC Research Notes, 2019, 12, 275.	1.4	19
8	Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clinical Genitourinary Cancer, 2018, 16, e11-e21.	1.9	9
9	Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. Npj Breast Cancer, 2018, 4, 32.	5.2	27
10	Design and rationale for the I nfluenza vaccination A fter M yocardial I nfarction (IAMI) trial. A registry-based randomized clinical trial. American Heart Journal, 2017, 189, 94-102.	2.7	39
11	JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Molecular Cancer Therapeutics, 2017, 16, 1645-1657.	4.1	18
12	Single cell dynamic phenotyping. Scientific Reports, 2016, 6, 34785.	3.3	16
13	Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). Scientific Reports, 2016, 6, 22435.	3.3	7
14	A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Scientific Reports, 2016, 6, 29752.	3.3	50
15	Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Medicine, 2016, 8, 54.	8.2	12
16	Quantifying differences in cell line population dynamics using CellPD. BMC Systems Biology, 2016, 10, 92.	3.0	21
17	The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Informatics, 2015, 14s4, CIN.S19338.	1.9	59
18	Stochasticity and determinism in cancer creation and progression. Convergent Science Physical Oncology, 2015, 1, 026003.	2.6	3

#	Article	IF	Citations
19	Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).. Journal of Clinical Oncology, 2014, 32, 7-7.	1.6	17
20	A physical sciences network characterization of non-tumorigenic and metastatic cells. Scientific Reports, 2013, 3, 1449.	3.3	146
21	A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results.. Journal of Clinical Oncology, 2013, 31, 59-59.	1.6	7
22	The sciences converge to fight cancer. Nature Physics, 2012, 8, 773-774.	16.7	6